Marla C. Dubinsky, MD
Marla C. Dubinsky, MD, an internationally recognized leader in pediatric inflammatory bowel disease (IBD), was one of three national recipients of the 2022 Sherman Prize.
The award, which recognizes individuals for pioneering achievements that have transformed patient care and rewards outstanding achievements in Crohn’s Disease and Ulcerative Colitis, was announced September 21 by the Bruce and Cynthia Sherman Charitable Foundation.
Dr. Dubinsky is Professor of Pediatrics and Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai. She is also Chief of the Division of Pediatric Gastroenterology at the Mount Sinai Kravis Children’s Hospital and Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai.
In its announcement, the Foundation cited Dr. Dubinsky as “one of IBD’s preeminent game changers” and said she has been “giving hope to children and their parents for decades.” The Foundation added, “Dr. Dubinsky works on being a guiding figure for those coming up the ranks, teaching her mentees to tailor care to a patient’s needs and reinforcing the importance of empowering patients to better manage their IBD so they can live the life they want.”
Her work has included defining therapeutic dosing levels of medicines to optimize treatment in children; identifying some of the most predictive biomarkers for disease progression; and bringing intestinal ultrasound to the bedside. In addition, she is the co-founder of Trellus Health, a publicly traded digital health company based in London and New York that has a goal of improving care for people with chronic conditions. The other co-founder is Laurie Keefer, PhD, Professor of Psychology and Director for Psychobehavioral Research within the Division of Gastroenterology.
“I am both humbled and honored to be one of the 2022 Sherman Prize recipients,” said Dr. Dubinsky. “It is truly an honor to be recognized for your life’s passion and this award inspires me to keep pushing forward and continuing to impact the lives of patients with IBD.”
Uma Mahadevan, MD, Professor of Medicine, Director of the Colitis and Crohn’s Disease Center, and Director of the Advanced IBD Fellowship at the University of California San Francisco in San Francisco was also awarded the Sherman Prize. Both Sherman Prize honorees receive a prize of $100,000.
Parambir S. Dulai, MD, Associate Professor of Medicine in the Division of Gastroenterology and Hepatology, Director of GI Clinical Trials and Precision Medicine, and Director of the Digestive Health Foundation BioRepository at Northwestern University in Evanston, Illinois, received the Sherman Emerging Leader Prize Honoree, which includes a $25,000 prize.